Alterity Therapeutics
Nasdaq ATHE · Melbourne, Australia
Works in Cardiovascular · Metabolic & endocrine · Neurology
Alterity Therapeutics is a clinical trial sponsor based in Melbourne, Australia, listed as Nasdaq ATHE. It has 1 active clinical trial with 7 planned participants, in Cardiovascular, Metabolic & endocrine and Neurology. Since 2021 it has completed 2 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq ATHE
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Alterity Therapeutics
Alterity Therapeutics is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 7 planned participants, in Cardiovascular, Metabolic & endocrine, Neurology. Since 2021 it has completed 2 trials and stopped 0 early.
Alterity Therapeutics is based in Melbourne, Australia and is listed as Nasdaq ATHE. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Alterity Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Approve Suite is not affiliated with Alterity Therapeutics. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.